News | December 19, 2006

Payor Backs Door to Balloon Initiative

UnitedHealthcare has announced its support for the “Door to Balloon (D2B): An Alliance for Quality” campaign recently initiated by the ACC and supported by 22 partnering organizations including the American Heart Association (AHA). The campaign aims to improve door to balloon time, which is the interval between a patient’s arrival at the hospital and the opening of a blocked artery with an angioplasty balloon. Patients who receive prompt treatment are more likely to survive a common type of heart attack.

The consumer health benefits company had incorporated D2B as one of the quality measurements in its UnitedHealth Premium designation program for cardiac facilities nationwide. The tangible outcome of its support will be demonstrated by increasing the weight of measurement assigned to the D2B performance standard — a facility that lowers D2B time will receive a higher quality score.

Under the UnitedHealth Premium program, facilities seeking designation status must submit clinical outcomes data, resulting in increased access to unparalleled datasets on performance against cardiac care criteria established by recognized experts that cardiac facilities, physicians and patients can use to make informed choices.

“We believe that providing hospitals, physicians and health care professionals with evidence-based information they can use to analyze clinical performance is one of the most important ways to improve clinical quality,” said Reed Tuckson, M.D., executive vice president and chief of medical affairs for UnitedHealth Group in a press release. “We commend the American College of Cardiology and the American Heart Association for taking a leadership role to improve timeliness of treatment, representing an important opportunity to improve the quality of patient care. This should come as welcome news for the millions of Americans – and their families – who suffer from heart disease and expect to receive the best care and information.”

Related Content

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init